Melatonin prolongs islet graft survival in diabetic NOD mice

Journal of Pineal Research

Volumn 47, Issue 3, 2009, Pages 284-292

  Lin, Gu Jiun ^a   Huang, Shing Hwa ^b   Chen, Yuan Wu ^b   Hueng, Dueng Yuan ^b,c   Chien, Ming Wei ^a   Chia, Wei Tso ^d   Chang, Deh Ming ^c   Sytwu, Huey Kang ^a  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b National Defense Medical Center ^*

^c TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^d Hsin Chu General Hospital   (Taiwan)

Author keywords

Autoimmune recurrence; Islet transplantation; Melatonin; Non obese diabetic mice; Type 1 diabetes mellitus

Indexed keywords

CYTOKINE; INTERLEUKIN 10; MELATONIN;

ANIMAL EXPERIMENT; ARTICLE; AUTOIMMUNITY; CELL PROLIFERATION; CONTROLLED STUDY; DIABETES MELLITUS; FLOW CYTOMETRY; GRAFT SURVIVAL; MOUSE; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; SPLEEN CELL; TH1 CELL; TH2 CELL;

ANIMALS; BLOOD GLUCOSE; CENTRAL NERVOUS SYSTEM DEPRESSANTS; FLOW CYTOMETRY; GRAFT SURVIVAL; INSULIN; ISLETS OF LANGERHANS TRANSPLANTATION; MELATONIN; MICE; MICE, INBRED NOD; POLYMERASE CHAIN REACTION; T-LYMPHOCYTES;

EID: 69949125268     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/j.1600-079X.2009.00712.x     Document Type: Article

References (55)

1. Kawasaki E, Abiru N, Eguchi K. Prevention of type 1 diabetes: from the view point of beta cell damage. Diabetes Res Clin Pract 2004 66 (Suppl 1 S27 S32.
2. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993 329 : 977 986.
3. Hypoglycemia in the Diabetes Control and Complications Trial. The Diabetes Control and Complications Trial Research Group. Diabetes 1997 46 : 271 286.
4. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998 352 : 837 853.
5. Aoki CA, Borchers AT, Ridgway WM et al. NOD mice and autoimmunity. Autoimmun Rev 2005 4 : 373 379.
6. Wicker LS, Todd JA, Peterson LB. Genetic control of autoimmune diabetes in the NOD mouse. Annu Rev Immunol 1995 13 : 179 200.
7. Koarada S, Wu Y, Olshansky G et al. Increased nonobese diabetic Th1:Th2 (IFN-gamma:IL-4) ratio is CD4 + T cell intrinsic and independent of APC genetic background. J Immunol 2002 169 : 6580 6587.
8. Cameron MJ, Arreaza GA, Zucker P et al. IL-4 prevents insulitis and insulin-dependent diabetes mellitus in nonobese diabetic mice by potentiation of regulatory T helper-2 cell function. J Immunol 1997 159 : 4686 4692.
9. Pennline KJ, Roque-Gaffney E, Monahan M. Recombinant human IL-10 prevents the onset of diabetes in the nonobese diabetic mouse. Clin Immunol Immunopathol 1994 71 : 169 175.
10. Gaglia JL, Shapiro AM, Weir GC. Islet transplantation: progress and challenge. Arch Med Res 2005 36 : 273 280.
11. Balamurugan AN, Bottino R, Giannoukakis N et al. Prospective and challenges of islet transplantation for the therapy of autoimmune diabetes. Pancreas 2006 32 : 231 243.
12. Okitsu T, Bartlett ST, Hadley GA et al. Recurrent autoimmunity accelerates destruction of minor and major histoincompatible islet grafts in nonobese diabetic (NOD) mice. Am J Transplant 2001 1 : 138 145.
13. Gysemans CA, Waer M, Valckx D et al. Early graft failure of xenogeneic islets in NOD mice is accompanied by high levels of interleukin-1 and low levels of transforming growth factor-beta mRNA in the grafts. Diabetes 2000 49 : 1992 1997.
14. Young HY, Zucker P, Flavell RA et al. Characterization of the role of major histocompatibility complex in type 1 diabetes recurrence after islet transplantation. Transplantation 2004 78 : 509 515.
15. Sibley RK, Sutherland DE, Goetz F et al. Recurrent diabetes mellitus in the pancreas iso- and allograft. A light and electron microscopic and immunohistochemical analysis of four cases. Lab Invest 1985 53 : 132 144.
16. Tyden G, Reinholt FP, Sundkvist G et al. Recurrence of autoimmune diabetes mellitus in recipients of cadaveric pancreatic grafts. N Engl J Med 1996 335 : 860 863.
17. Tan DX, Manchester LC, Hardeland R et al. Melatonin: a hormone, a tissue factor, an autocoid, a paracoid, and an antioxidant vitamin. J Pineal Res 2003 34 : 75 78.
18. Reiter RJ. The melatonin rhythm: both a clock and a calendar. Experientia 1993 49 : 654 664.
19. Malpaux B, Migaud M, Tricoire H et al. Biology of mammalian photoperiodism and the critical role of the pineal gland and melatonin. J Biol Rhythms 2001 16 : 336 347.
20. Maldonado MD, Murillo-Cabezas F, Terron MP et al. The potential of melatonin in reducing morbidity-mortality after craniocerebral trauma. J Pineal Res 2007 42 : 1 11.
21. Peyrot F, Ducrocq C. Potential role of tryptophan derivatives in stress responses characterized by the generation of reactive oxygen and nitrogen species. J Pineal Res 2008 45 : 235 246.
22. Reiter RJ, Tan DX, Terron MP et al. Melatonin and its metabolites: new findings regarding their production and their radical scavenging actions. Acta Biochim Pol 2007 54 : 1 9.
23. Bubenik GA. Thirty four years since the discovery of gastrointestinal melatonin. J Physiol Pharmacol 2008 59 (Suppl 2 33 51.
24. Jaworek J, Brzozowski T, Konturek SJ. Melatonin as an organoprotector in the stomach and the pancreas. J Pineal Res 2005 38 : 73 83.
25. Carrillo-Vico A, Guerrero JM, Lardone PJ et al. A review of the multiple actions of melatonin on the immune system. Endocrine 2005 27 : 189 200.
26. Pioli C, Caroleo MC, Nistico G et al. Melatonin increases antigen presentation and amplifies specific and non specific signals for T-cell proliferation. Int J Immunopharmacol 1993 15 : 463 468.
27. Currier NL, Sun LZ, Miller SC. Exogenous melatonin: quantitative enhancement in vivo of cells mediating non-specific immunity. J Neuroimmunol 2000 104 : 101 108.
28. Raghavendra V, Singh V, Kulkarni SK et al. Melatonin enhances Th2 cell mediated immune responses: lack of sensitivity to reversal by naltrexone or benzodiazepine receptor antagonists. Mol Cell Biochem 2001 221 : 57 62.
29. Shaji AV, Kulkarni SK, Agrewala JN. Regulation of secretion of IL-4 and IgG1 isotype by melatonin-stimulated ovalbumin-specific T cells. Clin Exp Immunol 1998 111 : 181 185.
30. Raghavendra V, Singh V, Shaji AV et al. Melatonin provides signal 3 to unprimed CD4(+) T cells but failed to stimulate LPS primed B cells. Clin Exp Immunol 2001 124 : 414 422.
31. Conti A, Maestroni GJ. Role of the pineal gland and melatonin in the development of autoimmune diabetes in non-obese diabetic mice. J Pineal Res 1996 20 : 164 172.
32. Sapmaz E, Ayar A, Celik H et al. Effects of melatonin and oxytetracycline in autologous intraperitoneal ovary transplantation in rats. Neuro Endocrinol Lett 2003 24 : 350 354.
33. Jung FJ, Yang L, Harter L et al. Melatonin in vivo prolongs cardiac allograft survival in rats. J Pineal Res 2004 37 : 36 41.
34. Hung JT, Liao JH, Lin YC et al. Immunopathogenic role of TH1 cells in autoimmune diabetes: evidence from a T1 and T2 doubly transgenic non-obese diabetic mouse model. J Autoimmun 2005 25 : 181 192.
35. Peschke E. Melatonin, endocrine pancreas and diabetes. J Pineal Res 2008 44 : 26 40.
36. Peschke E, Wolgast S, Bazwinsky I et al. Increased melatonin synthesis in pineal glands of rats in streptozotocin induced type 1 diabetes. J Pineal Res 2008 45 : 439 448.
37. Stumpf I, Muhlbauer E, Peschke E. Involvement of the cGMP pathway in mediating the insulin-inhibitory effect of melatonin in pancreatic beta-cells. J Pineal Res 2008 45 : 318 327.
38. Ramracheya RD, Muller DS, Squires PE et al. Function and expression of melatonin receptors on human pancreatic islets. J Pineal Res 2008 44 : 273 279.
39. Konakchieva R, Kyurkchiev S, Kehayov I et al. Selective effect of methoxyindoles on the lymphocyte proliferation and melatonin binding to activated human lymphoid cells. J Neuroimmunol 1995 63 : 125 132.
40. Garcia-Maurino S, Gonzalez-Haba MG, Calvo JR et al. Melatonin enhances IL-2, IL-6, and IFN-gamma production by human circulating CD4 + cells: a possible nuclear receptor-mediated mechanism involving T helper type 1 lymphocytes and monocytes. J Immunol 1997 159 : 574 581.
41. Garcia-Maurino S, Pozo D, Carrillo-Vico A et al. Melatonin activates Th1 lymphocytes by increasing IL-12 production. Life Sci 1999 65 : 2143 2150.
42. Maestroni GJ, Conti A, Pierpaoli W. Pineal melatonin, its fundamental immunoregulatory role in aging and cancer. Ann NY Acad Sci 1988 521 : 140 148.
43. Inserra P, Zhang Z, Ardestani SK et al. Modulation of cytokine production by dehydroepiandrosterone (DHEA) plus melatonin (MLT) supplementation of old mice. Proc Soc Exp Biol Med 1998 218 : 76 82.
44. Scott B, Liblau R, Degermann S et al. A role for non-MHC genetic polymorphism in susceptibility to spontaneous autoimmunity. Immunity 1994 1 : 73 83.
45. Wang H, Wei W, Wang NP et al. Melatonin ameliorates carbon tetrachloride-induced hepatic fibrogenesis in rats via inhibition of oxidative stress. Life Sci 2005 77 : 1902 1915.
46. Lahiri S, Singh P, Singh S et al. Melatonin protects against experimental reflux esophagitis. J Pineal Res 2009 46 : 207 213.
47. Zhang YC, Pileggi A, Agarwal A et al. Adeno-associated virus-mediated IL-10 gene therapy inhibits diabetes recurrence in syngeneic islet cell transplantation of NOD mice. Diabetes 2003 52 : 708 716.
48. Kim YH, Lim DG, Wee YM et al. Viral IL-10 gene transfer prolongs rat islet allograft survival. Cell Transplant 2008 17 : 609 618.
49. Prud'homme GJ. Gene therapy of autoimmune diseases with vectors encoding regulatory cytokines or inflammatory cytokine inhibitors. J Gene Med 2000 2 : 222 232.
50. Balasa B, Van Gunst K, Jung N et al. IL-10 deficiency does not inhibit insulitis and accelerates cyclophosphamide-induced diabetes in the nonobese diabetic mouse. Cell Immunol 2000 202 : 97 102.
51. Kuhn R, Lohler J, Rennick D et al. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993 75 : 263 274.
52. Groux H, O'garra A, Bigler M et al. A CD4 + T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997 389 : 737 742.
53. Hardeland R, Pandi-Perumal SR. Melatonin, a potent agent in antioxidative defense: actions as a natural food constituent, gastrointestinal factor, drug and prodrug. Nutr Metab (Lond) 2005 2 : 22.
54. Kucukakin B, Lykkesfeldt J, Nielsen HJ et al. Utility of melatonin to treat surgical stress after major vascular surgery - a safety study. J Pineal Res 2008 44 : 426 431.
55. Gitto E, Pellegrino S, Gitto P et al. Oxidative stress of the newborn in the pre- and postnatal period and the clinical utility of melatonin. J Pineal Res 2009 46 : 128 139.